Ella Lemelbaum Institute for Immuno-Oncology
The Ella Lemelbaum Institute is internationally recognized as a leading medical facility for treating melanoma and skin cancer. Using the latest technologies and research-based techniques, we implement some of the most innovative therapies available, such as TIL immunotherapy. We also offer patients the option to participate in advanced clinical research trials in the field of melanoma treatment. Services at the Ella Institute are all-inclusive, caring for patients from diagnosis through monitoring and follow-up.
Located on Sheba Medical Center’s vast campus, the Ella Institute collaborates with exceptional cancer centers worldwide, including the National Institutes of Health (NIH) in the United States. Our top-tier institute exists due to the generosity of the Lemelbaum family, in memory of their daughter Ella.
The Cancer Research Center at Sheba
The Ella Institute is part of Sheba’s Cancer Research Center, where we are continuously immersed in clinical and pre-clinical research. Our mission is to improve diagnostic and treatment methods for patients with melanoma and skin cancer. Alongside the focus on academic teaching and training, Sheba’s physicians also work in tandem with major pharmaceutical and biotech companies and prominent international research groups. We conduct many clinical studies to develop new anti-cancer drugs with the aid of progressive technologies.
Programs at our Cancer Research Center include:
What diseases do we treat?
At the Ella Institute, we offer advanced treatment for melanoma and skin cancer.
What treatments do we offer?
Sheba is one of the few hospitals worldwide to offer innovative TIL (Tumor-Infiltrating Lymphocytes) immunotherapy as a treatment for patients with metastatic melanoma. This type of cellular immunotherapy stimulates the immune system to produce a stronger, focused response against tumor cells, effectively turning the body’s natural immune system into a cancer killer.
Immune Checkpoint Inhibitors
This drug blocks specific proteins that are produced by some types of immune system cells, such as T-cells and certain cancer cells. The function of these proteins is to help control the body’s immune responses, such as by preventing T-cells from attacking cancer cells. Therefore, by blocking particular proteins, the T-cells and immune system can destroy cancer cells more efficiently. We offer treatment with immune checkpoint inhibitors to help treat melanoma and skin cancer.
Surgical removal of the cancerous tissue (such as a mole) is the primary treatment for early-stage melanoma. If melanoma has spread to lymph nodes in surrounding tissues, surgery may also be performed to remove the affected nodes.
Chemotherapy drugs to destroy cancer cells can be administered intravenously or with oral pills.
High-powered energy beams are used to destroy cancer cells. Radiotherapy is sometimes used after surgery or to alleviate melanoma symptoms when the disease has spread to other parts of the body.
Also known as biological therapy, specialized drugs are used to target specific vulnerable parts of the cancer cells. Approximately half of melanomas carry particular mutations that can be suppressed by targeted therapy drugs, preventing the cancer cells from multiplying.
Nethanel Asher, MD
Senior Physician, Oncology Specialist, Ella Lemelbaum Institute for Immuno-Oncology
Dr. Asher received his board certification in medical oncology and now focuses on clinical diagnosis, management and treatment of melanoma patients. Dr. Asher’s interests include the toxicity profiles of immuno-therapeuthic agents and combinations; practice and quality of care development; oncologic education and collaboration with medical; surgical and dermatologic teams; oncologic patients’ quality of life and attitudes towards participation in clinical trials.
Dov Zippel, MD
Head of the Meirav Breast Center
Surgery Specialist, Ella Lemelbaum Institute for Immuno-Oncology
Dr. Zippel specializes in melanoma treatment and intraperitoneal chemotherapy. He received his medical degree from Tel Aviv University and completed his residency at Sheba. Dr. Zippel also completed a sub-residency in surgical oncology at the University of Calgary, Canada.
Holistic Healthcare at Sheba
At the Ella Institute, we treat melanoma and skin cancer with a patient-centric approach that considers your whole body – not just the cancer. World-class clinicians customize every treatment program with a focus on your quality of life. Our multidisciplinary staff includes medical oncologists, pathologists, dermatologists, surgeons, specialized nurses, and researchers who every patient with supportive, integrative care. At Sheba, you will benefit from advanced therapies that are based on groundbreaking research and take into account your unique needs – physical, psychological, and social. All healthcare services are provided conveniently on our comprehensive campus.